Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study

BACKGROUND: The 2021 Canadian Cardiovascular Society guidelines recommend proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with atherosclerotic cardiovascular disease whose low-density lipoprotein cholesterol (LDL-C) concentration remains ≥ 1.8 mmol/L despite maxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Milan, Mancini, G.B. John, Wani, Rajvi J., Ahooja, Vineeta, Bergeron, Jean, Manjoo, Priya, Pandey, A. Shekhar, Reiner, Maureen, Beltran, Johnny, Oliveira, Thiago, Mackinnon, Erin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207771/
https://www.ncbi.nlm.nih.gov/pubmed/35734519
http://dx.doi.org/10.1016/j.cjco.2022.03.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207771/
https://www.ncbi.nlm.nih.gov/pubmed/35734519
http://dx.doi.org/10.1016/j.cjco.2022.03.003

Ejemplares similares